Entrada Therapeutics Unveils Promising DMD and DM1 Data Plans for 2026

Entrada Therapeutics (NASDAQ: TRDA) recently presented its strategic vision for 2026 at the Guggenheim 2026 Emerging Outlook Biotech Summit, highlighting a series of anticipated clinical data releases focused on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). CEO Dipal Doshi emphasized the company’s commitment to developing innovative intracellular therapeutics through its proprietary delivery mechanisms.

Based in Boston, Entrada employs approximately 150–160 staff members dedicated to advancing therapies that can effectively penetrate cell membranes. Doshi outlined the company’s pipeline, which is currently led by promising programs targeting DMD and DM1, and described 2026 as a “data-rich year” filled with multiple clinical updates.

Key Developments in DMD Therapy

For DMD, Entrada plans to release crucial clinical data for two exon-skipping programs, specifically targeting exon 44 and exon 45. Doshi noted that the first readout for exon 44, involving a dosage of 6 mg/kg, will focus on both safety and dystrophin production. He explained that this regimen includes 5 mg/kg of the conjugate and 1 mg/kg of the delivery vehicle. Doshi expressed optimism about observing double-digit dystrophin levels in the initial cohort at this dosage.

He referenced comparative data from Avidity’s del-zota program, which reported approximately 25% dystrophin above background levels, indicating that Entrada anticipates exceeding these figures in its subsequent exon 44 cohort.

Doshi distinguished Entrada’s cyclic cell-penetrating peptide chemistry from traditional linear peptide approaches, asserting that the company’s unique chemical structure has shown safety in preclinical trials involving mice, non-human primates, and healthy volunteers.

Assessing Functional Benefits and Regulatory Strategies

While dystrophin remains a central biomarker in these studies, Doshi reiterated that functional benefits are ultimately what patients and clinicians seek. For the initial cohorts in both exon 44 and exon 45, safety and dystrophin production will be prioritized. He cautioned that functional changes may take longer to manifest in exon 44 patients, who typically present background dystrophin levels of around 6%–10%.

In contrast, exon 45 patients, with lower background levels, might show functional improvements sooner. The study structure includes a 19-week period with three doses, followed by an open-label phase lasting approximately 39 weeks. Doshi suggested that a year of dosing and follow-up could provide a clearer picture of functional benefit.

Entrada is also strategizing around its U.S. enrollment plans. The company has received FDA approval to commence a study on adult patients and aims to begin enrollment in the latter half of the year. Doshi indicated that the company will review the upcoming 6 mg/kg data before consulting with the FDA about increasing dosage limits for U.S. participants. Currently, the cap is approximately 1.28 mg/kg, a restriction Doshi attributes to FDA caution pending further safety data.

He acknowledged the ongoing dialogue with FDA officials, emphasizing that feedback from these discussions is being incorporated into their protocols.

As Entrada moves forward, Doshi expressed confidence that favorable results from the Q2 exon 44 dataset could serve to de-risk the broader portfolio of DMD programs, which also includes exon 45, 50, and 51, as well as a collaboration with Vertex for DM1.

Founded on the principles of enhancing drug delivery, Entrada Therapeutics is focused on creating protein-based therapeutics capable of addressing intracellular targets. The company utilizes its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology to tackle rare and serious diseases that have historically posed challenges for conventional biologics.

As the landscape of biotechnology evolves, Entrada’s ambitious initiatives in DMD and DM1 signal a strong commitment to innovation in therapeutic development, with significant implications for patients facing these devastating conditions.